BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry... Show more
a manufacturer of proprietary and generic bio preservation media products for cells, tissues and organs
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SNOU | 75.13 | 17.92 | +31.32% |
| T-Rex 2X Long SNOW Daily Target ETF | |||
| YBIT | 21.41 | 0.36 | +1.69% |
| Yieldmax Bitcoin Option Income Strategy ETF | |||
| EOD | 6.69 | 0.08 | +1.21% |
| Allspring Global Dividend Opportunity Fund | |||
| VTWV | 197.31 | 0.66 | +0.33% |
| Vanguard Russell 2000 Value ETF | |||
| OILU | 56.37 | -1.20 | -2.08% |
| MicroSectorsTM Oil&Gs Exp&Pd 3X Lvg ETNs | |||
A.I.dvisor indicates that over the last year, BLFS has been loosely correlated with RGEN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if BLFS jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To BLFS | 1D Price Change % | ||
|---|---|---|---|---|
| BLFS | 100% | -1.09% | ||
| RGEN - BLFS | 56% Loosely correlated | -1.93% | ||
| RVTY - BLFS | 51% Loosely correlated | -0.24% | ||
| A - BLFS | 50% Loosely correlated | -0.93% | ||
| XRAY - BLFS | 48% Loosely correlated | +1.24% | ||
| DHR - BLFS | 47% Loosely correlated | +0.53% | ||
More | ||||
| Ticker / NAME | Correlation To BLFS | 1D Price Change % |
|---|---|---|
| BLFS | 100% | -1.09% |
| Pharmaceuticals: Other industry (51 stocks) | 47% Loosely correlated | -0.35% |
| Pharmaceuticals industry (156 stocks) | 6% Poorly correlated | -0.77% |
The Stochastic Oscillator for BLFS moved into oversold territory on September 03, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 191 cases where BLFS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for BLFS moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BLFS as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for BLFS turned negative on August 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
BLFS broke above its upper Bollinger Band on August 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.137) is normal, around the industry mean (5.074). P/E Ratio (35.530) is within average values for comparable stocks, (144.044). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.260). Dividend Yield (0.000) settles around the average of (0.014) among similar stocks. P/S Ratio (16.502) is also within normal values, averaging (89.311).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.